Abstract
Clinical value and costs of G-CSF administration following autograft with mobilized peripheral blood progenitor cells (PBPC) were evaluated in two sequential groups of 20 patients each, treated for lymphoid neoplasms in the period February 1993 to January 1996. One group was given G-CSF (Filgrastim) (5 μg/kg/day), starting on day +1 until ANC was >500/μl, the other received no G-CSF. All patients were conditioned with mitoxantrone 60 mg/m2 + L-PAM 180 mg/m2 and received large numbers of PBPC (median of 12 and 13 × 106 CD34+/kg, respectively). The median time to ANC >500/μl was 10 days in the G-CSF group vs 14 days in controls (P < 0.0001). g-csf was associated with a slightly faster platelet recovery (11 vs 13 days to plts >20 000/μl, P = 0.09). Median duration of fever (2.5 vs 5 days, P = 0.028), nonprophylactic antibiotics (8 vs 11 days, P = 0.019), and post-transplant hospitalization (13 vs 16 days, P = 0.0028) were also significantly reduced. The average cost per treatment in the G-CSF group amounted to about US$18 241 as compared to US$21 868 in the control group, implying a cost reduction of approximately 16%. Thus, G-CSF reduced morbidity with cost containment, supporting its use even if autograft is performed with large quantities of PBPC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tarella, C., Castellino, C., Locatelli, F. et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 21, 401–407 (1998). https://doi.org/10.1038/sj.bmt.1701104
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701104
Keywords
This article is cited by
-
Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant
Indian Journal of Hematology and Blood Transfusion (2019)
-
A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation
Italian Journal of Pediatrics (2018)
-
Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation
Journal of Cancer Research and Clinical Oncology (2012)
-
Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs
Bone Marrow Transplantation (2010)
-
Optimal use of G-CSF administration after hematopoietic SCT
Bone Marrow Transplantation (2009)